Implant-based reconstruction, either a 2-stage expander/implant or a single-stage direct-to-implant approach, is currently the most frequently performed breast reconstruction procedure; almost 70% of breast reconstructions are performed using this approach.^[@R1]^ Advances in surgical techniques (skin-sparing and nipple-sparing mastectomy as well as the dual-plane technique) and implant technology have made excellent outcomes possible with implant-based reconstruction in appropriately selected patients. The shorter operative procedure without donor site morbidity and a quicker recovery have also made this procedure an attractive alternative to autologous procedures.

The introduction of acellular dermal matrices (ADMs) has further facilitated implant-based breast reconstruction. Placement of ADM at the inferolateral pole to provide reinforcement of the expander or implant pocket contributes to defining the inframammary and lateral mammary folds, prevents window shading of the pectoralis major muscle, and allows for improved implant positioning as compared with the complete submuscular coverage technique.^[@R2]--[@R5]^ In 2-stage procedures, the use of ADMs also allows for greater intraoperative expansion, thereby reducing the total number of fills and the time to complete tissue expansion.^[@R5]--[@R7]^ The technique of using ADM for lower pole reinforcement was first conceived with the use of AlloDerm (LifeCell Corporation, Branchburg, N.J.), a human ADM, about a decade ago^[@R2]--[@R5]^; since then, a variety of ADMs have become available and are used for this purpose. About half of all implant-based reconstructions are now being performed with ADM assistance.^[@R8]^

Despite the advances in implant-based breast reconstruction, a persistent issue with this approach is the optimization of outcomes when performed in conjunction with radiotherapy. Both pre- and postreconstruction radiotherapy can lead to significant increases in complications (infection, skin necrosis, and capsular contracture) and poor outcomes (including reconstructive failure).^[@R9]--[@R12]^ When the indication for radiotherapy is known preoperatively, the tendency is to delay reconstruction to after completion of radiotherapy and to use an autologous flap procedure as the reconstructive option. Patients, on the contrary, may not be amenable to delaying reconstruction or undergoing a flap procedure. Thus, there is a need to ameliorate the outcome of implant-based reconstruction in the setting of radiotherapy. Experimental evidence suggests that ADMs may provide a protective effect on breasts with implants that are irradiated after implantation.^[@R13]^ Furthermore, the deleterious effect of irradiation does not seem to affect the viability and integration of ADM implanted in an irradiated field or when irradiated after implantation.^[@R14],[@R15]^ Clinical data on the use of ADM in conjunction with radiotherapy is, however, sparse^[@R16],[@R17]^, and no definitive conclusions can be made regarding the protective effect of ADM, if any.

The purpose of this study was to assess the postoperative complications associated with the use of a porcine acellular dermal matrix (PADM, Strattice; LifeCell Corporation) in implant-based breast reconstruction and, in particular, to assess the complications and outcomes of patients who had received radiotherapy. The effect of the timing of radiotherapy on outcomes was also assessed.

PATIENTS AND METHODS
====================

Patients who underwent immediate, PADM-assisted, implant-based breast reconstruction (2-stage or single-stage) postmastectomy in the author's practice between January 2009 and May 2013 with at least 1 year of follow-up (from the date of surgery) were included in this study. Patients who had prior breast reconstructive surgery or augmentation mammaplasty or those who had implant-based flap procedures were excluded. This is a single-center, single-surgeon study that was approved by the local institutional review board.

Single-stage or 2-stage breast reconstructive surgery with PADM assistance was performed in a similar manner to those described with the use of human ADM.^[@R2]--[@R5]^ In the author's opinion, the technical details of importance for a successful outcome are aggressive antibiotic irrigation of the mastectomy pocket, adequate intraoperative expansion, and adequate drainage. After creation of a subpectoral pocket for the implant or tissue expander, copious antibiotic (bacitracin in saline) irrigation of the breast pocket was performed with a triple antibiotic solution. The implant or expander was also rinsed with the antibiotic solution before introduction into the breast pocket. This strict antibiotic protocol is important to minimize the risk of postoperative infection and the chronic inflammatory response that infection might cause.^[@R18]^ When tissue expanders were used, care was exercised not to overexpand intraoperatively as this would place undue stress on the overlying upper mastectomy flap and increase the risk of ischemia and skin necrosis. At the same time, adequate intraoperative expansion was ensured such that PADM placed at the lower breast pole was in direct contact with the lower mastectomy flap to allow for recellularization and revascularization of the matrix. In both single-stage and 2-stage procedures, one drain each was placed in the retropectoral and subcutaneous spaces to ensure adequate drainage to reduce the risk of seroma formation.

Patient records were reviewed retrospectively. Preoperative demographic data, including age, body mass index, and comorbid conditions known to influence postoperative outcomes (obesity and tobacco use),^[@R19]^ were collected. The duration of follow-up and adjunctive therapy use (chemotherapy or radiotherapy) and its timing (prereconstruction or postreconstruction) were recorded. All postoperative complications (type and incidence) that were recorded during the follow-up period were analyzed. Comparisons of complications in irradiated vs nonirradiated breasts were performed using Fisher's exact test. Statistical significance was set at a *P*-value of \<0.05. Prereconstruction radiotherapy was performed before mastectomy as part of breast conserving surgery. Postreconstruction radiotherapy was performed after tissue expansion in those undergoing a 2-stage procedure or after implant placement in those undergoing a single-stage procedure.

RESULTS
=======

A total of 103 patients met the inclusion criteria. Baseline demographic and clinical characteristics of these patients are listed in [Table 1](#T1){ref-type="table"}. Of note, 27% of the patients were obese and 18% used tobacco. A total of 158 reconstructions, 48 unilateral and 55 bilateral, were performed. About half of the patients received chemotherapy (16% preoperatively, 22% postoperatively, and 13% both pre- and postoperatively) and a quarter of the breasts had been irradiated (12% preoperatively, 12% postoperatively, and 1% pre- and postoperatively).

###### 

Patient Demographics, Adjuvant Therapy, and Mastectomy Procedures Performed
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Patients were followed for a minimum of 1 year (mean, 36.2 ± 7.6 mo; range, 23.0--50.4 mo) from initial surgery. During this period, complications occurred in 17 breasts for a total complication rate of 10.8% in this series. The clinical characteristics of the patients and their complications are described in [Table 2](#T2){ref-type="table"}. The incidence of individual complications and the overall rate of complications in the study population are provided in [Table 3](#T3){ref-type="table"}. Complications included 13 cases of implant/expander loss (8.2%), 9 cases of infection (5.7%), 6 cases of dehiscence (3.8%), 3 cases of incision-site eschar (1.9%), and 1 case each of ischemia, hematoma, and seroma (0.6% each) ([Table 3](#T3){ref-type="table"}). Of the 13 cases of implant/expander loss, 8 were secondary to infection (7 with methicillin-resistant *Staphylococcus aureus* and 1 with *Pseudomonas aeruginosa*), 3 were secondary to dehiscence, 1 was secondary to infection (with methicillin-resistant *S. aureus*) and dehiscence, and 1 was secondary to multiple ischemic episodes. Two cases of dehiscence were successfully reoperated and repaired without further issues. Of the 17 breasts with complications, 9 had been irradiated. Compared with nonirradiated breasts, the rate of total complications and implant/expander loss and dehiscence were significantly higher in irradiated breasts ([Table 3](#T3){ref-type="table"}). All 9 irradiated breasts with complications were irradiated before reconstruction. There were no complications in breasts that had been irradiated postreconstruction ([Table 4](#T4){ref-type="table"}). Interestingly, the patient who was irradiated both prereconstruction and postreconstruction had no complications.
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Clinical Characteristics and Complications of Patients
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###### 

Complications Stratified by Radiation Status
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###### 

Complications Stratified by Timing of Radiotherapy
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DISCUSSION
==========

PADM is a relatively recent addition to the growing list of ADM products available for use in breast surgery. It offers ease of use after a 2-minute soak in saline solution with no polarity and is available in large sizes. Clinical experience with its use in breast reconstruction includes 4 dedicated series in the published literature.^[@R20]--[@R23]^ Israeli and Feingold^[@R20]^ performed PADM-assisted 2-stage reconstructions in 44 patients and reported an overall complication rate of 16.9% after stage 1 reconstruction (77 reconstructions) and 10.4% after stage 2 reconstruction (67 reconstructions). Stage 1 complications included tissue expander loss (13%), infection (10.4%), skin necrosis (7.8%), seroma (5.2%), and hematoma (1.3%). Stage 2 complications during a follow-up period of 8--345 days included infection (3%), seroma (3%), implant loss (3%), and capsular contracture (grade III/IV, 4.5%). In 27 single-stage breast reconstructions, Himsl et al^[@R21]^ reported that the use of PADM was associated with predictable and acceptable esthetic and haptic outcomes with reduced risks of fibrosis and reconstructive failure. Complications in this series included 2 cases each of skin complications and fibrosis (capsular contracture ranking was no higher than Baker grade I) and 1 case each of implant malposition and soft-tissue thinning at 6 months of follow-up. Glasberg and Light^[@R22]^ used PADM in 144 2-stage reconstructions and reported consistent outcomes with its use. The overall complication rate in this series was 6.3% (including infection/cellulitis 2.1%, expander loss 1.4%, flap necrosis 1.4%, and seroma 1.4%) with an absence of clinically significant capsular contracture (Baker grade III/IV) at a mean follow-up of 14 months.^[@R22]^ Salzberg et al^[@R23]^ used PADM in 105 predominantly single-stage reconstructions and reported low complication rates (total complication, 8.6%) and good outcomes. Furthermore, with a mean follow-up of 41.4 months, they reported no incidence of long-term complications, such as capsular contracture or implant malposition.

In this study, PADM was used in 158 reconstructions (single- and 2-stage). The overall complication rate of 10.8% is comparable to those reported by Glasberg and Light^[@R22]^ and Israeli and Feingold^[@R20]^ (second stage) in their series of PADM-assisted reconstructions, thus supporting the observation that consistent outcomes can be obtained with the use of PADM. Furthermore, the complication rates in the present series also compare favorably with those reported with standard breast reconstruction using the total submuscular coverage technique^[@R24]^ ([Table 5](#T5){ref-type="table"}). The comparable complication rate between these 2 approaches is reassuring and indicates that the use of Strattice does not elevate complications beyond those that are to be expected with implant-based breast reconstruction. The only exception was reconstructive failure which was about 8.2% in this series; the high rate seems to be associated with the use of adjuvant radiotherapy. In nonirradiated breasts, reconstructive failure was 4.2%.
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Complications Associated with PADM-Assisted Reconstructions Compared with Standard Reconstructions via the Total Submuscular Coverage Technique
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The adjunctive use of radiotherapy in implant-based breast reconstruction has consistently been shown to be associated with increased postoperative complications and poor outcomes, both historically and in the current era, despite improvements in radiotherapy delivery methods and protocols and in implant designs.^[@R9]--[@R12],[@R25]^ Radiotherapy adversely affects the skin causing thickening and fibrosis and alters hair, sweat, and sebaceous gland function required for reepithelialization and wound repair, thus compromising wound healing.^[@R26],[@R27]^ Consequently, complications of wound dehiscence, infection, reconstructive failure, and capsular contracture are elevated in the setting of radiotherapy. Whether the use of ADM is able to minimize the effects of radiotherapy is unclear given the lack of clinical data. However, experimental data suggest that human ADM decreases radiation-related inflammation and delays or diminishes pseudoepithelium formation around capsules, which is a precursor to the formation of a fibrotic capsule in humans.^[@R13]^

In this study, wound dehiscence and expander/implant loss were found to be significantly higher in irradiated vs nonirradiated breasts, which is consistent with the adverse effects of radiotherapy on skin and wound healing. In addition, the infection rate was also elevated in irradiated breasts although this did not reach statistical significance. Others have also reported higher complications in breasts reconstructed with ADMs in the setting of radiotherapy compared with no radiotherapy.^[@R5],[@R16],[@R20],[@R28]--[@R32]^

Analysis of the data by timing of radiotherapy suggests that PADM may protect against postreconstruction radiotherapy. None of the breasts that were irradiated postreconstruction were found to have complications in this series. Of most significance, physical examination of these patients revealed irradiated reconstructed breasts that seemed symmetrical to the nonirradiated reconstructed contralateral breasts and similar in pliability and texture. In contrast to postreconstruction irradiated breasts, half of breasts (9 of 19) that had been irradiated prereconstruction had complications. The dehiscence rate of 26% and failure rate of 42% in breast irradiated prereconstruction in the present study are comparable to those reported in breasts that had been irradiated prereconstruction and then underwent standard submuscular reconstructions (dehiscence 22% and reconstructive failure 40%).^[@R9],[@R10]^ Albeit a small sample, these data support the paradigm that implant-based breast reconstruction is better avoided in patients who have undergone premastectomy radiotherapy and that an autologous procedure would be more appropriate.^[@R33]^

The absence of complications in patients who had received postreconstruction radiotherapy is a significant finding in this study because previous studies suggested that the timing of radiotherapy with respect to ADM placement did not impact the complication rate and that in general complications were higher in irradiated vs nonirradiated patients.^[@R16],[@R31]^ However, similar to our study, a recent study by Seth et al^[@R34]^ also noted that ADM may be advantageous in patients undergoing postoperative radiation therapy. They reported no significance difference in complication rates between nonirradiated and irradiated patients (irradiated during tissue expansion stage) who underwent breast reconstruction with ADM assistance, but complication rates were significantly higher in irradiated patients who underwent standard reconstruction without ADM assistance compared with nonirradiated patients. Because we did not have non-PADM control groups, which is a limitation of this study, we reviewed published studies to assess the complications in prereconstruction and postreconstruction irradiated breasts that had been reconstructed using the standard submuscular approach. Nava et al^[@R11]^ noted a 40% failure rate with postreconstruction radiation therapy on tissue expanders and a 6.4% failure rate with postreconstruction radiation therapy on permanent implants vs a 2.3% failure rate in nonirradiated breasts. Lin et al^[@R10]^ reported a 43.8% complication rate with prereconstruction irradiation, a 41.2% complication rate with irradiation during reconstruction, and a 13.8% complication rate with no radiation exposure. Both of these recent studies indicate a high incidence of complications and reconstructive failure when radiotherapy is delivered postreconstruction, which is in contrast to the absence of complication with the use of PADM in this study and further supports the observation of a possible protective benefit with the use of PADM with postreconstruction radiation. The reason for the protective effect of PADM in postreconstruction but not prereconstruction radiotherapy remains to be elucidated, but it could be related to differences in the extent of revascularization and repopulation of PADM in the 2 settings. This, however, cannot be verified because histologic analyses of implanted PADM were not performed, which is another limitation of this study.

CONCLUSIONS
===========

This study demonstrates that the addition of porcine acellular dermal matrix to implant-based reconstructions is associated with acceptable complication rates that are comparable to those observed in standard reconstructions using the submuscular approach. In the setting of adjunctive radiotherapy, complications, especially infection, dehiscence, and reconstructive failure, are increased in accordance with the adverse effects of radiotherapy on the skin and wound healing. However, it seems that porcine acellular dermal matrix may protect against the adverse effects of postreconstruction radiotherapy. There were no complications in breasts that had been irradiated postreconstruction in this series. Further controlled studies are needed to elucidate this finding.
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